These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12917315)

  • 21. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
    Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
    Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of pneumococcal vaccination on hospitalization and exacerbations in elderly Japanese chronic obstructive pulmonary disease patients.
    Yamaya M; Fujino N; Kubo H; Arai H
    Geriatr Gerontol Int; 2009 Jun; 9(2):206-9. PubMed ID: 19490143
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence.
    Fedson DS
    Lancet Infect Dis; 2003 May; 3(5):272-3; discussion 273-4. PubMed ID: 12726973
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Splenectomy and pneumococcal vaccination].
    Postma MJ; Heijnen MA; de Vries R; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1141-2; author reply 1142. PubMed ID: 12822527
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
    Cai L; Uchiyama H; Yanagisawa S; Kamae I
    Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-pneumococcal vaccination in elderly persons].
    Trivalle C
    Presse Med; 1998 Mar; 27(10):484-8. PubMed ID: 9767984
    [No Abstract]   [Full Text] [Related]  

  • 29. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine.
    Hendrickson DJ; Blumberg DA; Joad JP; Jhawar S; McDonald RJ
    Pediatr Infect Dis J; 2008 Nov; 27(11):1030-2. PubMed ID: 18845981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost benefits of targeting the pneumococcal vaccination program to the elderly population in Taiwan.
    Chen YH; Yang GY; Loh CH; Liou SH; Su WL; Lin SH; Chou CC
    Am J Infect Control; 2006 Nov; 34(9):597-9. PubMed ID: 17097456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal vaccination.
    de Roux A; Lode H
    Eur Respir J; 2005 Dec; 26(6):982-3. PubMed ID: 16319323
    [No Abstract]   [Full Text] [Related]  

  • 32. Preventing pneumococcal infections in older adults.
    Nuorti P; Reingold A
    Lancet Respir Med; 2015 Nov; 3(11):834-6. PubMed ID: 26607821
    [No Abstract]   [Full Text] [Related]  

  • 33. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia.
    Fisman DN; Abrutyn E; Spaude KA; Kim A; Kirchner C; Daley J
    Clin Infect Dis; 2006 Apr; 42(8):1093-101. PubMed ID: 16575726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
    Metlay JP; Fishman NO; Joffe M; Edelstein PH
    Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine doesn't lower pneumonia risk in the elderly.
    Levenson D
    Rep Med Guidel Outcomes Res; 2003 May; 14(10):8-9. PubMed ID: 12870488
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C; Reinert RR; von der Schulenburg JM
    Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Marchetti M; Colombo GL
    Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC; Baughman W; Schmotzer B; Farley MM
    Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.